Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I (CARE-MS I): A Phase 3 Study in Relapsing-Remitting Treatment-Naive Patients

Authors
Category Primary study
Conference64th American Academy of Neurology (AAN) Annual Meeting; 2012 Apr 21-28; New Orleans, LA, United States. Neurology
Year 2012
This article has no abstract
Epistemonikos ID: 4f7e0918a1113a5ce14653386084280375df259a
First added on: Aug 10, 2018